Anti-hepatocarcinoma effects of 5-fluorouracil encapsulated by galactosylceramide liposomes in vivo and in vitro

Figure 1 5-Fu-GCL; TEM ×4000.

Figure 2 Effects of various concentrations of 5-Fu-GCL on the proliferation of HepA cells analyzed by cell counts. ^aP<0.05, ^bP<0.01 vs control. ^cP<0.05 vs free 5-Fu (mean±SD, n = 5).

Figure 3 Effects of various concentrations of 5-Fu-GCL on the rate of cell growth inhibition of HepA cells analyzed by MTT assay (mean±SD, n = 5).

Figure 4 Concentration-time course of 5-Fu-GCL in intracellular fluid of HepA cells analyzed by HPLC assay (mean±SD, n = 5).

Figure 5 Results of flow cytometry analysis of HepA cells treated with Fu-GCL for 48 h and DNA content was determined by flow cytometry (mean±SD, n = 5). A: control; B: 5-Fu-GCL; C: free 5-Fu; D: apoptosis percentage of HepA cells treated with Fu-GCL. ^aP<0.05 vs 5-F-Fu.

Figure 6 Effects of 5-Fu-GCL on cell cycle phase distribution (mean±SD, n = 5). ^aP<0.05, ^bP<0.01 vs control. ^cP<0.05 vs free 5-Fu. A: G₀/G₁ phase; B: S phase; C: G₂/M phase.